Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
The study cohort comprises samples from patients whose tumors have been prospectively characterized as part of their care at Memorial Sloan Kettering Cancer Center. This includes a variety of distinct tumor type and molecular subtypes.
- Study Weblinks:
- Study Design:
- Case Set
- Study Type:
- Case Set
- Total number of consented subjects: 1660
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
DNA samples from tumor tissue were from patients at Memorial Sloan Kettering Cancer Center. Tumor and normal sample libraries prepared for targeted MSK-IMPACT sequencing were recaptured for exome sequencing. Study participants were not selected on the basis of tumor type, molecular features of their tumor, or treatments.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
- Authorized Data Access Requests
-
See articles in PMC citing this study accession
- Study Attribution
-
-
Principal Investigator
- David B. Solit. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
-
Investigators
- Barry S. Taylor. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Alexander E. Drilon. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Ezra Y. Rosen. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Sandra D'Angelo. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Hikmat Al-Ahmadie. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Nikolaus Schultz. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Mark Donoghue. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
-
Funding Sources
- U54 OD020355. National Institutes of Health, Bethesda, MD, USA.
- P01 CA221757. National Institutes of Health, Bethesda, MD, USA.
- R01 CA207244. National Institutes of Health, Bethesda, MD, USA.
- P50 CA092629. National Institutes of Health, Bethesda, MD, USA.
- R01 CA251591-01A1. National Institutes of Health, Bethesda, MD, USA.
- 2T32 CA009512-29A1. National Institutes of Health, Bethesda, MD, USA.
- I10-0084. Starr Cancer Consortium, USA.
- 1P50CA217694-01A1. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- R01 CA233899. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- P50 CA221745. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- UL1-TR002384. National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
- P30-CA008748. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- R01 CA245069. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- R01 CA204749. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- R01 CA227534. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator